Cambium Bio Ltd Market Cap ($6.96 Million)
Market Cap & Net Worth: Cambium Bio Ltd (CMB)
Cambium Bio Ltd market cap. Cambium Bio Ltd (AU:CMB) has a market capitalization of $6.96 Million (AU$9.84 Million) as of November 7, 2026. Listed on the AU stock exchange, this Australia-based company holds position #27771 globally and #1377 in its home market, demonstrating a -14.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cambium Bio Ltd's stock price AU$0.36 by its total outstanding shares 27331918 (27.33 Million). Also see how efficiently does Cambium Bio Ltd generate cash for how efficiently the company converts equity into cash flow.
Cambium Bio Ltd Market Cap History (2015–2026)
Cambium Bio Ltd market cap history from 2015 to 2026. Data shows change from $177.69 Million to $6.96 Million (-27.04% CAGR). Check CMB stock price and chart for real-time trading data and today's change.
Cambium Bio Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cambium Bio Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Cambium Bio Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
13.57x
Cambium Bio Ltd's market cap is 13.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $311.90 Million | $1.74 Million | -$3.57 Million | 179.72x | N/A |
| 2017 | $236.28 Million | $9.99 Million | $3.27 Million | 23.64x | 72.25x |
| 2018 | $340.25 Million | $575.41K | -$5.18 Million | 591.32x | N/A |
| 2019 | $168.25 Million | $25.08K | -$6.02 Million | 6709.33x | N/A |
| 2020 | $241.74 Million | $1.66 Million | -$894.05K | 145.33x | N/A |
| 2021 | $154.71 Million | $7.07 Million | $2.76 Million | 21.89x | 56.07x |
| 2024 | $7.74 Million | $719.00 | -$2.26 Million | 10758.87x | N/A |
| 2025 | $9.09 Million | $670.06K | -$3.84 Million | 13.57x | N/A |
Competitor Companies of CMB by Market Capitalization
Companies near Cambium Bio Ltd in the global market cap rankings as of November 7, 2026. Also see CMB current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Cambium Bio Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Cambium Bio Ltd (2015–2026)
Market capitalization of Cambium Bio Ltd from 2015 to today. Between 2015 and today, Cambium Bio Ltd's market cap moved from $177.69 Million to $ 6.96 Million, with a yearly change of -27.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$6.96 Million | -23.40% |
| 2025 | AU$9.09 Million | +17.50% |
| 2024 | AU$7.74 Million | +33.33% |
| 2023 | AU$5.80 Million | -93.75% |
| 2022 | AU$92.83 Million | -40.00% |
| 2021 | AU$154.71 Million | -36.00% |
| 2020 | AU$241.74 Million | +43.68% |
| 2019 | AU$168.25 Million | -50.55% |
| 2018 | AU$340.25 Million | +44.00% |
| 2017 | AU$236.28 Million | -24.24% |
| 2016 | AU$311.90 Million | +75.53% |
| 2015 | AU$177.69 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Cambium Bio Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.96 Million USD |
| MoneyControl | $6.96 Million USD |
| MarketWatch | $6.96 Million USD |
| marketcap.company | $6.96 Million USD |
| Reuters | $6.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing i… Read more